132 related articles for article (PubMed ID: 12440275)
21. Alglucerase enzyme replacement therapy used safely and effectively throughout the whole pregnancy of a Gaucher disease patient.
Aporta Rodriguez R; Escobar Vedia JL; Navarro Castro AM; Aguilar García G; Cabrera Torres A
Haematologica; 1998 Sep; 83(9):852-3. PubMed ID: 9825582
[TBL] [Abstract][Full Text] [Related]
22. Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease - a histological study.
Rudzki Z; Okoń K; Machaczka M; Rucińska M; Papla B; Skotnicki AB
Eur J Haematol; 2003 May; 70(5):273-81. PubMed ID: 12694162
[TBL] [Abstract][Full Text] [Related]
23. Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy.
Elstein D; Abrahamov A; Altarescu G; Zimran A
Blood Cells Mol Dis; 2013 Feb; 50(2):140. PubMed ID: 23085428
[No Abstract] [Full Text] [Related]
24. [Analysis of the densitometric method of hand bone radiograms and assessment of early changes of bone structure in the children with Gaucher s disease on enzyme replacement therapy (ERT)].
Lysoń-Wojciechowska G; Skawiński W; Tylki-Szymańska A
Pediatr Endocrinol Diabetes Metab; 2007; 13(3):159-64. PubMed ID: 17880827
[TBL] [Abstract][Full Text] [Related]
25. [The treatment of Gaucher's disease in The Netherlands using enzyme substitution therapy].
Hollak CE; van Oers MH; Maaswinkel P; Aerts JM; Goudsmit R
Ned Tijdschr Geneeskd; 1996 May; 140(19):1011-3. PubMed ID: 8684492
[No Abstract] [Full Text] [Related]
26. Enzyme replacement therapy in type III Gaucher disease.
Tylki-Szymańska A; Czartoryska B
J Inherit Metab Dis; 1999 Apr; 22(2):203-4. PubMed ID: 10234625
[No Abstract] [Full Text] [Related]
27. Enzyme-replacement therapy for Gaucher's disease.
N Engl J Med; 1991 Dec; 325(25):1809-11. PubMed ID: 1944489
[No Abstract] [Full Text] [Related]
28. Bone marrow involvement in Gaucher disease at MRI : what long-term evolution can we expect under enzyme replacement therapy?
Fedida B; Touraine S; Stirnemann J; Belmatoug N; Laredo JD; Petrover D
Eur Radiol; 2015 Oct; 25(10):2969-75. PubMed ID: 25875285
[TBL] [Abstract][Full Text] [Related]
29. Oxidative stress, trace elements, and circulating microparticles in patients with Gaucher disease before and after enzyme replacement therapy.
Zahran AM; Elsayh KI; El-Deek SE; El-Baz MA
Clin Appl Thromb Hemost; 2015 Jan; 21(1):58-65. PubMed ID: 23698728
[TBL] [Abstract][Full Text] [Related]
30. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
31. Histological characterisation of visceral changes in a patient with type 2 Gaucher disease treated with enzyme replacement therapy.
Tezuka Y; Fukuda M; Watanabe S; Nakano T; Okamoto K; Kuzume K; Yano Y; Eguchi M; Ishimae M; Ishii E; Miyazaki T
Blood Cells Mol Dis; 2018 Feb; 68():194-199. PubMed ID: 27866810
[TBL] [Abstract][Full Text] [Related]
32. Enzyme replacement therapy in Gaucher's disease.
Kasturi L; Amin SA
Indian Pediatr; 2001 Jun; 38(6):686-8. PubMed ID: 11418745
[No Abstract] [Full Text] [Related]
33. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients.
Zimran A; Hollak CE; Abrahamov A; van Oers MH; Kelly M; Beutler E
Blood; 1993 Aug; 82(4):1107-9. PubMed ID: 8353277
[TBL] [Abstract][Full Text] [Related]
34. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
Drelichman G; Ponce E; Basack N; Freigeiro D; Aversa L; Graciela E; Kohan R
J Pediatr; 2007 Aug; 151(2):197-201. PubMed ID: 17643778
[TBL] [Abstract][Full Text] [Related]
35. Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease.
Donald A; Björkvall CK; Vellodi A; ; Cox TM; Hughes D; Jones SA; Wynn R; Machaczka M
Orphanet J Rare Dis; 2022 Jun; 17(1):234. PubMed ID: 35717194
[TBL] [Abstract][Full Text] [Related]
36. Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy.
Mitrovic M; Sumarac Z; Antic D; Bogdanovic A; Elezovic I; Vukosavljevic D; Ignjatovic S; Majkic-Singh N; Suvajdzic N
Blood Cells Mol Dis; 2012 Jun; 49(1):58-9. PubMed ID: 22459893
[No Abstract] [Full Text] [Related]
37. Gaucher disease with nephrotic syndrome: response to enzyme replacement therapy.
Santoro D; Rosenbloom BE; Cohen AH
Am J Kidney Dis; 2002 Jul; 40(1):E4. PubMed ID: 12087590
[TBL] [Abstract][Full Text] [Related]
38. Reconversion of bone marrow in Gaucher disease treated with enzyme therapy documented by MR.
Allison JW; James CA; Arnold GL; Stine KC; Becton DL; Bell JM
Pediatr Radiol; 1998 Apr; 28(4):237-40. PubMed ID: 9545478
[TBL] [Abstract][Full Text] [Related]
39. Platelet function and coagulation abnormalities in type 1 Gaucher disease patients: effects of enzyme replacement therapy (ERT).
Giona F; Palumbo G; Amendola A; Santoro C; Mazzuconi MG
J Thromb Haemost; 2006 Aug; 4(8):1831-3. PubMed ID: 16879228
[No Abstract] [Full Text] [Related]
40. Enzyme replacement therapy in type I Gaucher disease.
Kay AC; Saven A; Garver P; Thurston DW; Rosenbloom BF; Beutler E
Trans Assoc Am Physicians; 1991; 104():258-64. PubMed ID: 1845151
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
